These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35091470)

  • 1. Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors.
    Lai LP; Fer N; Burgan W; Wall VE; Xu B; Soppet D; Esposito D; Nissley DV; McCormick F
    Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35091470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
    Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics.
    Boned Del Río I; Young LC; Sari S; Jones GG; Ringham-Terry B; Hartig N; Rejnowicz E; Lei W; Bhamra A; Surinova S; Rodriguez-Viciana P
    Proc Natl Acad Sci U S A; 2019 Jul; 116(27):13330-13339. PubMed ID: 31213532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
    Jones GG; Del Río IB; Sari S; Sekerim A; Young LC; Hartig N; Areso Zubiaur I; El-Bahrawy MA; Hynds RE; Lei W; Molina-Arcas M; Downward J; Rodriguez-Viciana P
    Nat Commun; 2019 Jun; 10(1):2532. PubMed ID: 31182717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
    Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
    Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
    Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.
    Rukhlenko OS; Khorsand F; Krstic A; Rozanc J; Alexopoulos LG; Rauch N; Erickson KE; Hlavacek WS; Posner RG; Gómez-Coca S; Rosta E; Fitzgibbon C; Matallanas D; Rauch J; Kolch W; Kholodenko BN
    Cell Syst; 2018 Aug; 7(2):161-179.e14. PubMed ID: 30007540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
    Andreadi C; Cheung LK; Giblett S; Patel B; Jin H; Mercer K; Kamata T; Lee P; Williams A; McMahon M; Marais R; Pritchard C
    Genes Dev; 2012 Sep; 26(17):1945-58. PubMed ID: 22892241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.
    Ishii N; Harada N; Joseph EW; Ohara K; Miura T; Sakamoto H; Matsuda Y; Tomii Y; Tachibana-Kondo Y; Iikura H; Aoki T; Shimma N; Arisawa M; Sowa Y; Poulikakos PI; Rosen N; Aoki Y; Sakai T
    Cancer Res; 2013 Jul; 73(13):4050-4060. PubMed ID: 23667175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration.
    Rajalingam K; Wunder C; Brinkmann V; Churin Y; Hekman M; Sievers C; Rapp UR; Rudel T
    Nat Cell Biol; 2005 Aug; 7(8):837-43. PubMed ID: 16041367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling.
    McKay MM; Ritt DA; Morrison DK
    Curr Biol; 2011 Apr; 21(7):563-8. PubMed ID: 21458265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis.
    Young LC; Hartig N; Boned Del Río I; Sari S; Ringham-Terry B; Wainwright JR; Jones GG; McCormick F; Rodriguez-Viciana P
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10576-E10585. PubMed ID: 30348783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.
    Degirmenci U; Wang M; Hu J
    Cells; 2020 Jan; 9(1):. PubMed ID: 31941155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
    Packer LM; Rana S; Hayward R; O'Hare T; Eide CA; Rebocho A; Heidorn S; Zabriskie MS; Niculescu-Duvaz I; Druker BJ; Springer C; Marais R
    Cancer Cell; 2011 Dec; 20(6):715-27. PubMed ID: 22169110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation.
    Li Y; Takahashi M; Stork PJS
    J Biol Chem; 2013 Sep; 288(38):27646-27657. PubMed ID: 23893412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.